365 related articles for article (PubMed ID: 34160549)
1. The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity.
Ma S; Yan J; Barr T; Zhang J; Chen Z; Wang LS; Sun JC; Chen J; Caligiuri MA; Yu J
J Exp Med; 2021 Aug; 218(8):. PubMed ID: 34160549
[TBL] [Abstract][Full Text] [Related]
2. The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function.
Mapperley C; van de Lagemaat LN; Lawson H; Tavosanis A; Paris J; Campos J; Wotherspoon D; Durko J; Sarapuu A; Choe J; Ivanova I; Krause DS; von Kriegsheim A; Much C; Morgan M; Gregory RI; Mead AJ; O'Carroll D; Kranc KR
J Exp Med; 2021 Mar; 218(3):. PubMed ID: 33156926
[TBL] [Abstract][Full Text] [Related]
3. SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs.
Hou G; Zhao X; Li L; Yang Q; Liu X; Huang C; Lu R; Chen R; Wang Y; Jiang B; Yu J
Nucleic Acids Res; 2021 Mar; 49(5):2859-2877. PubMed ID: 33577677
[TBL] [Abstract][Full Text] [Related]
4. METTL3-mediated m
Song H; Song J; Cheng M; Zheng M; Wang T; Tian S; Flavell RA; Zhu S; Li HB; Ding C; Wei H; Sun R; Peng H; Tian Z
Nat Commun; 2021 Sep; 12(1):5522. PubMed ID: 34535671
[TBL] [Abstract][Full Text] [Related]
5. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
Zhang C; Huang S; Zhuang H; Ruan S; Zhou Z; Huang K; Ji F; Ma Z; Hou B; He X
Oncogene; 2020 Jun; 39(23):4507-4518. PubMed ID: 32366907
[TBL] [Abstract][Full Text] [Related]
6. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
7. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
Du C; Lv C; Feng Y; Yu S
J Exp Clin Cancer Res; 2020 Oct; 39(1):223. PubMed ID: 33087165
[TBL] [Abstract][Full Text] [Related]
8. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
[TBL] [Abstract][Full Text] [Related]
9. YTHDF2 promotes mitotic entry and is regulated by cell cycle mediators.
Fei Q; Zou Z; Roundtree IA; Sun HL; He C
PLoS Biol; 2020 Apr; 18(4):e3000664. PubMed ID: 32267835
[TBL] [Abstract][Full Text] [Related]
10. Interferon-stimulated gene 20 (ISG20) selectively degrades N6-methyladenosine modified Hepatitis B Virus transcripts.
Imam H; Kim GW; Mir SA; Khan M; Siddiqui A
PLoS Pathog; 2020 Feb; 16(2):e1008338. PubMed ID: 32059034
[TBL] [Abstract][Full Text] [Related]
11. The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells.
Dixit D; Prager BC; Gimple RC; Poh HX; Wang Y; Wu Q; Qiu Z; Kidwell RL; Kim LJY; Xie Q; Vitting-Seerup K; Bhargava S; Dong Z; Jiang L; Zhu Z; Hamerlik P; Jaffrey SR; Zhao JC; Wang X; Rich JN
Cancer Discov; 2021 Feb; 11(2):480-499. PubMed ID: 33023892
[TBL] [Abstract][Full Text] [Related]
12. The m6A Reader YTHDF2 Promotes Bladder Cancer Progression by Suppressing RIG-I-Mediated Immune Response.
Zhang L; Li Y; Zhou L; Zhou H; Ye L; Ou T; Hong H; Zheng S; Zhou Z; Wu K; Yan Z; Thiery JP; Cui J; Wu S
Cancer Res; 2023 Jun; 83(11):1834-1850. PubMed ID: 36939388
[TBL] [Abstract][Full Text] [Related]
13. N6-methyladenosine modification and the YTHDF2 reader protein play cell type specific roles in lytic viral gene expression during Kaposi's sarcoma-associated herpesvirus infection.
Hesser CR; Karijolich J; Dominissini D; He C; Glaunsinger BA
PLoS Pathog; 2018 Apr; 14(4):e1006995. PubMed ID: 29659627
[TBL] [Abstract][Full Text] [Related]
14. m6A Reader YTHDF2 Regulates LPS-Induced Inflammatory Response.
Yu R; Li Q; Feng Z; Cai L; Xu Q
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875984
[TBL] [Abstract][Full Text] [Related]
15. m
Qi M; Sun H; Guo Y; Zhou Y; Gu X; Jin J; Chen X; Wang F; Ma H; Guo X; Chen H; Shen B
Cell Prolif; 2022 Jan; 55(1):e13164. PubMed ID: 34850470
[TBL] [Abstract][Full Text] [Related]
16. YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis.
Hua Z; Wei R; Guo M; Lin Z; Yu X; Li X; Gu C; Yang Y
Oncogene; 2022 Mar; 41(10):1482-1491. PubMed ID: 35075244
[TBL] [Abstract][Full Text] [Related]
17. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
[TBL] [Abstract][Full Text] [Related]
18. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.
Yang Z; Cai Z; Yang C; Luo Z; Bao X
EBioMedicine; 2022 Jun; 80():104019. PubMed ID: 35490460
[TBL] [Abstract][Full Text] [Related]
19. YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A-dependent DAPK3 degradation.
Bai X; Chen J; Zhang W; Zhou S; Dong L; Huang J; He X
Cancer Sci; 2023 Nov; 114(11):4299-4313. PubMed ID: 37700438
[TBL] [Abstract][Full Text] [Related]
20. Novel insights into roles of N6-methyladenosine reader YTHDF2 in cancer progression.
Liu R; Jia Y; Kong G; He A
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2215-2230. PubMed ID: 35763107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
